Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arthritis
One-year Phase III study shows Ilaris® offers rapid and sustained remission in patients with CAPS, a lifelong severe auto-inflammatory disease
June 24th, 2009
New results from a one-year Phase III study show that the investigational biological therapy Ilaris (canakinumab) produced rapid, complete and sustained remission in the majority of patients with a rare and potentially life-threatening auto-inflammatory disease called cryopyrin-associated periodic syndrome (CAPS). Data published in The New England Journal of Medicine show that patients experienced a benefit within hours of receiving a dose of Ilaris, and only needed further treatment every two months to control their disease. The primary objective of the study was the proportion of patients with disease flare on Ilaris compared to placebo during the second part of the...
Source: Vaccine Weekly (2009-06-24)
|
